Table 3 Five-years DDFS rates by stage category according to the anatomic and prognostic stage classifications
From: Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
Stage | Anatomic stage | Prognostic stage | ||
|---|---|---|---|---|
N (%) | 5-yr DDFS % (95% CI) | N (%) | 5-yr DDFS % (95% CI) | |
IA | 469 (37.7) | 96.6 (95.0–98.3) | 733 (58.9) | 95.7 (94.2–97.3) |
IB | 40 (3.2) | 94.1 (86.4–100) | 139 (11.2) | 91.4 (86.6–96.4) |
IIA | 399 (32.1) | 92.4 (89.7–95.2) | 201 (16.2) | 86.9 (82.2–91.9) |
IIB | 149 (12.0) | 87.3 (82.0–93.0) | 55 (4.4) | 85.0 (76.0–95.2) |
IIIA | 121 (9.7) | 81.3 (74.5–88.7) | 59 (4.7) | 77.6 (67.6–89.1) |
IIIB | – | – | 57 (4.6) | 67.7 (56.5–81.2) |
IIIC | 66 (5.3) | 70.5 (50.2–82.6) | – | – |